MicroRNA Biomarker Detection for Prostate Cancer Pathology Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches for managing low-risk prostate cancer, such as active surveillance, face challenges due to misclassification rates and the limitations of PSA as a surrogate for disease progression, leading to concerns about delayed treatment affecting disease cure.
Innovation Solution
The use of specific diagnostic microRNAs (miRNAs) like mir-19a, mir-19b, mir-519c-5p, and mir-345 for determining the likelihood of adverse prostate cancer pathology, allowing for more accurate treatment decisions by analyzing biological samples through methods like quantitative real-time PCR and incorporating additional risk factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If active surveillance is used to reduce treatment of low-risk prostate cancer, then unnecessary morbidities are reduced, but misclassification rates increase leading to delayed treatment of curable disease
Solution Approach 1:
The patent introduces microRNA biomarkers as intermediary molecules that mediate between clinical parameters and pathological outcomes. These biomarkers serve as a bridge to more accurately predict adverse pathology, enabling better classification of patients for active surveillance versus immediate treatment, thereby reducing misclassification while maintaining the benefits of surveillance protocols.
Solution Approach 2:
The patent implements a feedback mechanism by using microRNA expression levels to refine and adjust patient risk classification. The biomarker data provides feedback on the actual pathological risk, allowing clinicians to adjust surveillance intensity or initiate treatment based on molecular evidence rather than relying solely on traditional clinical parameters that lead to misclassification.
2Ease of operation
If PSA is used as a surrogate for disease progression, then monitoring is simplified, but accuracy in predicting adverse pathology decreases
Solution Approach 1:
The patent changes the measurement parameter from PSA levels to microRNA expression profiles. This parameter change maintains the simplicity of liquid-based testing while dramatically improving prediction accuracy for adverse pathology. The microRNA biomarkers provide more precise molecular information about tumor aggressiveness compared to the non-specific PSA surrogate.
3Loss of information
If biopsy sampling is performed to assess disease extent, then staging information is obtained, but sampling errors occur leading to inaccurate risk assessment
Solution Approach 1:
The patent extracts molecular information (microRNA expression) from the biological system that is independent of spatial sampling limitations. By taking out the diagnostic information from tissue architecture and extracting it at the molecular level in liquid samples, the method avoids the sampling errors inherent in biopsy-based staging while obtaining equivalent or superior prognostic information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the accuracy of predicting prostate cancer pathology, enabling more informed treatment decisions and potentially reducing unnecessary morbidities associated with radical interventions.
Implementation Method 1
The means of determining an amount of a diagnostic miRNA in a biological sample may vary. In some aspects, determining the amount of a diagnostic miRNA involves performing quantitative real-time PCR, such as multiplexed quantitative real-time PCR.
Data Source
AI summary
The present disclosure provides methods that find use in determining a likelihood of adverse prostate cancer pathology in a subject. The methods generally involve detection of one or more diagnostic microRNAs (miRNAs), such as mir-19a, mir-19b, mir-519c-5p, and/or mir-345 in a biological sample from the subject, such as blood or blood product. The detection of one or more such diagnostic miRNAs can be used to determine a likelihood of adverse prostate cancer pathology in a subject. The methods of the present disclosure also find use in facilitating treatment decisions for a subject. Also provided are devices, systems, and kits that may be used in practicing methods of the present disclosure.